These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16908373)

  • 1. Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis.
    Beck LA; Saini S
    J Am Acad Dermatol; 2006 Sep; 55(3):540-1; author reply 541-2. PubMed ID: 16908373
    [No Abstract]   [Full Text] [Related]  

  • 2. [Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit].
    Schmitt J; Schäkel K
    Hautarzt; 2007 Feb; 58(2):128, 130-2. PubMed ID: 17237929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.
    Amrol D
    South Med J; 2010 Jun; 103(6):554-8. PubMed ID: 20710140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema.
    Ramírez del Pozo ME; Contreras Contreras E; López Tiro J; Gómez Vera J
    J Investig Allergol Clin Immunol; 2011; 21(5):416-7. PubMed ID: 21905512
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab treatment in severe adult atopic dermatitis.
    Thaiwat S; Sangasapaviliya A
    Asian Pac J Allergy Immunol; 2011 Dec; 29(4):357-60. PubMed ID: 22299316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.
    Sheinkopf LE; Rafi AW; Do LT; Katz RM; Klaustermeyer WB
    Allergy Asthma Proc; 2008; 29(5):530-7. PubMed ID: 18926061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dermatological implications of omalizumab, an anti-IgE antibody].
    Di Lucca-Chrisment J
    Rev Med Suisse; 2015 Apr; 11(468):779-80, 782-3. PubMed ID: 26021140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab for the treatment of atopic dermatitis.
    Fernández-Antón Martínez MC; Leis-Dosil V; Alfageme-Roldán F; Paravisini A; Sánchez-Ramón S; Suárez Fernández R
    Actas Dermosifiliogr; 2012 Sep; 103(7):624-8. PubMed ID: 22056257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease.
    Lanier B
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S37-42. PubMed ID: 16722331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab for patients with severe and therapy-refractory atopic eczema?
    Andres C; Belloni B; Mempel M; Ring J
    Curr Allergy Asthma Rep; 2008 May; 8(3):179-80. PubMed ID: 18589835
    [No Abstract]   [Full Text] [Related]  

  • 11. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
    Scheinfeld N
    Dermatol Online J; 2005 Mar; 11(1):2. PubMed ID: 15748543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases.
    D'Amato G; Oldani V; Donner CF
    Monaldi Arch Chest Dis; 2003; 59(1):25-9. PubMed ID: 14533279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRI.
    Forman SB; Garrett AB
    Cutis; 2007 Jul; 80(1):38-40. PubMed ID: 17725062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis.
    Incorvaia C; Pravettoni C; Mauro M; Yacoub MR; Tarantini F; Riario-Sforza GG
    Monaldi Arch Chest Dis; 2008 Jun; 69(2):78-80. PubMed ID: 18837422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
    Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
    Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
    [No Abstract]   [Full Text] [Related]  

  • 16. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels.
    Belloni B; Ziai M; Lim A; Lemercier B; Sbornik M; Weidinger S; Andres C; Schnopp C; Ring J; Hein R; Ollert M; Mempel M
    J Allergy Clin Immunol; 2007 Nov; 120(5):1223-5. PubMed ID: 17936892
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis.
    Grundmann SA; Hemfort PB; Luger TA; Brehler R
    J Allergy Clin Immunol; 2008 Jan; 121(1):257-8. PubMed ID: 18206513
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study.
    Heil PM; Maurer D; Klein B; Hultsch T; Stingl G
    J Dtsch Dermatol Ges; 2010 Dec; 8(12):990-8. PubMed ID: 20678148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atopic dermatitis or hyper-IgE syndrome?
    Ohameje NU; Loveless JW; Saini SS
    Allergy Asthma Proc; 2006; 27(3):289-91. PubMed ID: 16913276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated IgE levels: two case reports and a literature review.
    Nečas M; Vašků V; Březinová E
    Acta Dermatovenerol Alp Pannonica Adriat; 2019 Jun; 28(2):89-92. PubMed ID: 31233174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.